IceCure Medical has entered an exclusive distribution agreement with Scovas Medical to market its ProSense® cryoablation systems in the Netherlands, targeting breast cancer and interventional oncology. This deal supports clinical education and physician access in a country known for interventional radiology expertise and interest in minimally invasive cancer treatments. The Netherlands is also the site of the Phase III THERMAC trial, which showed ProSense® cryoablation achieved the highest complete ablation rate with a 94% success rate and no complications. This partnership aims to expand ProSense® adoption, offering a less invasive alternative to surgery with potential benefits in patient quality of life and healthcare costs.
Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path ...
Alumis Inc. shares dropped 56.76% after its Phase 2b trial for a lupus drug failed to meet key goals, though some patient groups showed promise. Enovis Corporation shares fell 16.51% following its announcement to acquire eCential Robotics for €155 mi...
SPAC stocks like Rising Dragon Acquisition surged nearly 47% amid volatility, while biotech firm bioAffinity Technologies jumped 44% after a reverse stock split. Renewable energy company Fervo Energy gained 28% following a major geothermal power deal...
Enovis has lowered its price target to $27 from $30 following its binding offer to acquire eCential Robotics for €155 million. This acquisition aims to strengthen Enovis's position in surgical robotics and enhance its ASTRA technology ecosystem. Desp...
Citigroup reaffirmed its Buy rating on NIO but lowered the price target from $8.20 to $7.10 due to NIO's second-quarter deliveries and revenue missing company guidance and a third-quarter outlook below Wall Street estimates. Despite a 49.4% year-over...
